发明名称 |
Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles |
摘要 |
Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity. |
申请公布号 |
US8187638(B2) |
申请公布日期 |
2012.05.29 |
申请号 |
US20080235415 |
申请日期 |
2008.09.22 |
申请人 |
PUNNOOSE ALEX;KONGARA MADHUSUDAN R.;WINGETT DENISE;BOISE STATE UNIVERSITY |
发明人 |
PUNNOOSE ALEX;KONGARA MADHUSUDAN R.;WINGETT DENISE |
分类号 |
A61K9/14;A61K33/08;A61K33/30 |
主分类号 |
A61K9/14 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|